The protein levels of NOL7 were found to be notably increased in breast cancer, ovarian cancer, colon cancer, hepatocellular carcinoma, KIRC, adrenocortical carcinoma (RCC), LUAD, glioblastoma multiforme (GBM), and HNSC tissues (all p-values < 0.001) but decreased in PAAD tissues (p < 0.05) as compared with relevant healthy tissues (Figure 1c). Here, NOL7 is linked to hepatocellular carcinoma.